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Abstract The renin-angiotensin system (RAS) represents
an important target of antihypertensive medications.
Angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin II receptor blockers (ARB), which are widely-
used RAS inhibiting drugs, have been suggested to have
beneficial effects on bone tissue. We aimed to assess the
associations of use of ACEIs and/or ARBs with the risk of
fractures using a population-based prospective cohort and a
meta-analysis of published prospective cohort studies.
Information on antihypertensive medication use (including
both ACEIs and ARBs) were assessed in 1743 men and
women of the Kuopio Ischemic Heart Disease prospective
cohort study. Hazard ratios (HRs) [95% confidence inter-
vals (CI)] of ACEIs or ARBs use with incident fractures
were calculated. A total of 203 composite (hip, humeral,
and wrist) fractures occurred during a median follow-up of
14.8 years. In multivariate adjusted analysis, the HR for
composite fractures comparing users of ACEIs or ARBs
with non-users was 1.00 (0.59–1.69). The corresponding
adjusted HR for hip fractures comparing users versus non-
users of ACEIs or ARBs was 0.89 (0.32–2.47). Including
the current study, a total of 11 observational cohort studies
involving 3526,319 participants and [323,355 fractures
were included in a meta-analysis. Comparing ACEI users
with non-users and ARB users with non-users, the HRs for
composite fractures were 1.09 (0.89–1.33) and 0.87
(0.76–1.01) respectively. The corresponding HRs for hip
fractures were 0.91 (0.86–0.95) and 0.80 (0.75–0.85)
respectively. Use of RAS inhibitors was not associated
with long-term risk of composite fractures in both primary
and pooled analyses. Pooled evidence however suggests a
beneficial effect of RAS blockers on hip fracture risk.
Keywords Renin-angiotensin system  Angiotensin
converting enzyme  Angiotensin receptor blocker  Cohort
study  Fracture
Introduction
Aging of the population is associated with an increase in
age-related chronic conditions such as fractures (particu-
larly osteoporotic fractures). These are one of the most
common causes of disability worldwide and associated
with high health care costs [1, 2]. Complications of fracture
include morbidity, pain, limited function, reduction in
health-related quality of life, as well as mortality [3].
Mortality rates in the first year following hip fracture have
been reported to range from 10 to 50% [4, 5]. The
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prevention of fractures is therefore of public health
importance.
The majority of older people with osteoporosis have co-
morbidities such as hypertension and cardiovascular dis-
ease. Two major risk factors for osteoporotic fractures are
reduced bone mass and falls, and these have a close rela-
tionship with hypertension [6]. Elevated blood pressure or
diagnosed hypertension has been shown to be closely
associated with osteoporosis, decreased bone mineral
density (BMD), falls, as well as fractures [6–10]. Epi-
demiological evidence and studies in animal models sug-
gest that high blood pressure is associated with vitamin D
deficiency and abnormalities in calcium metabolism
[11, 12], which are known to be involved in the patho-
physiology of osteoporosis, falls, and fractures [13]. It
therefore appears that medications that lower blood pres-
sure may have a beneficial effect on bone tissue. Indeed,
blood pressure lowering medications such as thiazides and
b-blockers have consistently been shown to be associated
with the reduced risk of fractures [14–17]. Furthermore, the
renin-angiotensin system (RAS), that plays a vital role in
regulating blood pressure and electrolyte balance [18], and
the activation of which is an important contributor to sys-
temic hypertension [19], also has effects on bone tissue.
This is via the detrimental effects of angiotensin II, a pri-
mary mediator of numerous RAS functions, on the bone
[20]. Studies have shown that RAS activation induces
osteoporosis as well as reduces blood ionized calcium
levels [20, 21]. The RAS inhibiting drugs—angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin II
receptor blockers (ARB)—which respectively inhibit the
formation and signalling of angiotensin II peptide, may
have beneficial effects on bone tissue. Though improved
BMD as well as reductions in fracture risk have been
reported with the use of RAS inhibitors [14, 22–24], the
evidence has been inconsistent. Some studies, including a
previous meta-analysis, have also reported increases in
fracture risk as well as bone loss [25–29], whereas others
have shown no effects of RAS inhibitors on fracture risk
[14, 29]. In addition, the majority of studies on the topic
have been based on case–control designs [14, 24, 27],
therefore the temporal relationship between the use of (i.e.
exposure to) RAS inhibitors and their effect on future risk
of fractures is uncertain. RAS inhibitors in addition to
thiazides and b-blockers, are well established and widely
used drugs for the management of hypertension in people,
who are also prone to fractures; therefore, it will be clini-
cally useful if they are proven to reduce fracture risk. In
this context, this study aimed to investigate the prospective
effect of RAS inhibitors (ACEIs and ARBs) on the risk of
fractures using a population-based prospective cohort of
1743 middle-aged to elderly men and women from eastern
Finland. Furthermore, with the availability of a number of
published observational cohort studies that have evaluated
the associations between RAS inhibitors and risk of frac-
tures, this offered the opportunity to put the findings into
context by performing a systematic review and meta-
analysis.
Methods
We conducted the primary cohort analyses according to
STROBE (STrengthening the Reporting of OBservational
studies in Epidemiology) guidelines for reporting obser-
vational studies in epidemiology (Appendix 1 of Electronic
Supplementary Material) [30].
Study population
The study population formed part of the ongoing Kuopio
Ischaemic Heart Disease (KIHD) population-based
prospective cohort study, which was set up primarily to
investigate established and emerging risk factors for car-
diovascular disease and other additional health outcomes in
eastern Finland [31]. Participants comprised a randomly
selected sample of 2358 participants (1007 men and 1351
women) aged 53–74 years who resided in the town of Kuo-
pio or its surrounding rural communities and had baseline
assessments carried out betweenMarch 1998 and December
2001. Of the 2072 potentially eligible participants, 193
refused to participate, 66 did not respond to the invitation and
39 declined to give informed consent; leaving 1774 partici-
pants for the KIHD cohort. The current analysis included
1743 participants (913 women and 830 men) with non-
missing information on use of ACEIs or ARBs, relevant
covariates, and fracture outcomes (Appendix 2 of Electronic
Supplementary Material). The study protocol was approved
by the Research Ethics Committee of the University of
Eastern Finland and each participant gave written informed
consent according to the Declaration of Helsinki.
Exposure
Antihypertensive medications were classified based on
antihypertensive medication classes; all antihypertensives,
ACEIs or ARBs, b-blockers, calcium channel blockers, and
diuretics. Data on diagnosis of chronic diseases including
hypertension and the use of antihypertensive drugs were
assessed by self-administered questionnaires. These were
then cross-checked by a physician.
Fracture outcomes
We included all incident fractures, representing all hip,
humeral, and wrist fractures, that occurred from study entry
S. K. Kunutsor et al.
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to 2014. The endpoints assessed were incident composite,
hip, and wrist fractures. Composite fractures were defined
as hip, humeral, and wrist fractures. In the KIHD study,
participants are under annual continuous surveillance for
the development of new outcome events, including frac-
tures [32]. No losses to follow-up have so far been recor-
ded. Fracture incidence data were collected from the
National Hospital Discharge Register data by computer
linkage using Finnish personal identification codes as well
as a comprehensive review of hospital records, discharge
notes and diagnoses, and inpatient physician claims. The
events were coded according to the International Classifi-
cation of Diseases Tenth Revision (ICD-10) diagnostic
codes for fractures by site.
Assessment of risk markers
All baseline characteristics as well as risk markers were
assessed during the same visit at study entry. Methods for
collection of blood specimens and the measurement of
lipids and biochemical analytes have been previously
described in detail [33]. Briefly, besides fasting overnight
before blood collection, participants were told to abstain
from drinking alcohol for at least 3 days and from smoking
for at least 12 h before assessment. The cholesterol content
of lipoprotein fractions was measured from fresh samples
after combined ultracentrifugation and precipitation, and
serum triglycerides were assessed enzymatically (Boeh-
ringer Mannheim, Mannheim, Germany). Resting blood
pressure was measured between 8 and 10 a.m. with a
random-zero sphygmomanometer. Participants completed
self-administered health and lifestyle questionnaires for the
assessment of age, smoking, alcohol consumption, socio-
economic status (SES), prevalent diseases, medical history,
and use of medications [33]. Energy expenditure of phys-
ical activity was assessed using the validated KIHD
12-month leisure-time physical activity questionnaire
[34, 35].
Statistical analyses
Prospective cohort analyses
Baseline characteristics were presented as means (SD) or
median (interquartile range) for continuous variables and
percentages for categorical variables. Cox proportional
hazard regression models were used to conduct time-to-
event analyses after confirmation of the proportional haz-
ards assumptions [36]. Antihypertensive medication use
was categorised as no antihypertensive medication use,
diuretics use, b-blockers use, and ACEI or ARB use with
the use of dummy variables. Hazard ratios were progres-
sively adjusted for (i) age and sex; (ii) body mass index
(BMI), smoking, history of diabetes, systolic blood pres-
sure (SBP), prevalent hypertension, prevalent coronary
heart disease (CHD), history of heart failure, alcohol con-
sumption, and use of statins or calcium channel blockers;
and (iii) SES and physical activity. We evaluated effect
modification by pre-specified clinically relevant charac-
teristics using tests of interaction.
Systematic review and meta-analysis
We conducted a systematic review and meta-analysis of
observational cohort studies using a predefined protocol
and which was reported in accordance with PRISMA and
MOOSE guidelines [37, 38] (Appendices 3 and 4 of
Electronic Supplementary Material). Published observa-
tional population-based cohort (prospective, case cohort,
nested case–control, or retrospective) studies that evaluated
the associations between exposure to ACEIs or ARBs and
the risk of fractures, were sought using computer-based
databases (MEDLINE, EMBASE, and Web of Science)
from inception to April 2017. The computer-based searches
combined free and MeSH search terms and combined key
words related to the exposure (e.g., ‘‘angiotensin-convert-
ing enzyme inhibitors’’, ‘‘angiotensin II receptor blockers’’,
‘‘anti-hypertensive drugs’’) and outcome (e.g., ‘‘fracture’’).
There were no restrictions on language. Details of the
search strategy are reported in Appendix 5 of Electronic
Supplementary Material. After an initial screen of abstracts
and titles by one reviewer (S.K.K.), potentially relevant
articles were acquired. Each article was assessed by two
independent reviewers (S.K.K., M.R.W.) using the inclu-
sion criteria and any discrepancies regarding eligibility of
an article was discussed, and consensus reached with a
third author (J.A.L.). One author (S.K.K.) independently
extracted data and performed quality assessments using the
nine-star Newcastle–Ottawa Scale (NOS) [39] as described
previously [40]. Information was extracted on study char-
acteristics such as study design, publication year, geo-
graphical location, baseline age, duration of follow-up,
sample size and number of recorded fractures, and risk
estimates for the most adjusted models. A second reviewer
checked data with that in original articles. Summary
measures were presented as relative risks (RRs) with 95%
confidence intervals (CIs). Following Cornfield’s rare dis-
ease assumption [41], hazard ratios and odds ratios were
assumed to approximate the same measure of RR. Sum-
mary RRs were pooled using a random effects model to
minimize the effect of between-study heterogeneity [42].
Heterogeneity was assessed using the Cochrane v2 statistic
and the I2 statistic [43]. A narrative synthesis was per-
formed for studies that could not be pooled. All statistical
analyses were conducted using Stata version 14 (Stata
Corp, College Station, Texas).
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Results
Baseline characteristics
Table 1 provides a summary of baseline characteristics of
overall study participants and according to the develop-
ment of fractures. Of 1743 study participants, 736 (42.2%)
were on regular antihypertensive medication and of these,
249 (14.3%) were on ACEIs or ARBs. There were 830
(47.6%) male participants. The mean (SD) age and BMI of
study participants were 63 [7] years and 27.9 (4.5) kg/m2
respectively. Except for age, sex, history of CHD, waist-to-
hip ratio, and diastolic blood pressure, there were no sig-
nificant differences in baseline characteristics between
Table 1 Baseline participant characteristics overall and according to the development of fractures
Overall (N = 1743) Mean (SD),
median (IQR), or n (%)
Without fracture (N = 1540) Mean
(SD), median (IQR), or n (%)
With fracture (N = 203) Mean
(SD), median (IQR), or n (%)
P value*
Questionnaire/prevalent conditions
Age at survey
(years)
62.9 (6.5) 62.5 (6.4) 65.2 (6.4) \0.0001
Males 830 (47.6) 763 (50.0) 67 (33.0) \0.001
Alcohol
consumption (g/
week)
48.2 (100.4) 48.5 (101.6) 46.2 (91.2) 0.755
Socioeconomic
status
10.9 (4.7) 10.8 (4.7) 11.4 (4.6) 0.081
History of diabetes 140 (8.0) 123 (8.0) 17 (8.4) 0.849
Smoking status 228 (13.1) 203 (13.2) 25 (12.3) 0.731
History of
hypertension
722 (41.4) 637 (41.4) 85 (41.9) 0.890
History of CHD 488 (28.0) 418 (27.1) 70 (34.5) 0.029
History of heart
failure
129 (7.4) 108 (7.0) 21 (10.3) 0.088
Use of medication
Antihypertensives 736 (42.2) 643 (41.8) 93 (45.8) 0.271
Beta-blockers 457 (26.2) 396 (25.7) 61 (30.1) 0.187
CCBs 210 (12.1) 182 (11.8) 28 (13.8) 0.417
Diuretics 172 (9.9) 146 (9.5) 26 (12.8) 0.135
Statins 78 (4.5) 74 (4.8) 4 (2.0) 0.066
ACEIs and/or
ARBs
249 (14.3) 222 (14.4) 27 (13.3) 0.670
Physical measurements
BMI (kg/m2) 27.9 (4.5) 27.8 (4.4) 28.1 (4.7) 0.445
WHR 0.91 (0.09) 0.91 (0.09) 0.89 (0.09) 0.034
SBP (mmHg) 135.9 (17.3) 135.8 (17.3) 136.3 (17.0) 0.694
DBP (mmHg) 81.1 (9.0) 81.4 (9.0) 79.4 (8.3) 0.004
Physical activity
(kj/day)
477.6 (402.1) 482.5 (408.7) 441.0 (346.8) 0.166
Blood biomarkers
Total cholesterol
(mmol/l)
5.48 (0.96) 5.48 (0.95) 5.46 (1.05) 0.735
HDL-C (mmol/l) 1.25 (0.31) 1.25 (0.31) 1.28 (0.33) 0.192
Triglycerides
(mmol/l)**
1.12 (0.83–1.54) 1.12 (0.82–1.54) 1.13 (0.83–1.55) 0.554
Fasting plasma
glucose (mmol/l)
5.08 (1.21) 5.07 (1.18) 5.11 (1.39) 0.667
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, BMI body mass index, CCB calcium channel blocker, CHD
coronary heart disease, DBP diastolic blood pressure, GFR glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, IQR
interquartile range, SD standard deviation, SBP systolic blood pressure, WHR waist-to-hip ratio; *, based on t-tests; **, values were log-
transformed before conducting t-tests
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those who developed and did not develop fractures during
follow-up. Participants who experienced a fracture were
more likely to be older and have a history of CHD at
baseline compared with those who did not experience a
fracture. Males were less likely to experience a fracture
compared with females.
RAS inhibitors and risk of fractures
Prospective cohort analysis
During a median (interquartile range) follow-up of 14.8
(12.8–15.8) years, 203 incident composite fractures (annual
rate 8.76/1000 person-years at risk; 95% CI 7.63–10.05)
were recorded. Of the total number of incident fractures, 70
and 42 were hip and wrist fractures respectively. Com-
paring ACEIs or ARBs users with non-users, the age and
sex adjusted HR for composite fractures was 1.00 (95% CI
0.66–1.52; P = 0.992), which remained non-significant
following further adjustment for several risk factors (BMI,
smoking, history of diabetes, SBP, prevalent hypertension,
CHD, or heart failure, alcohol consumption, and use of
statins or calcium channel blockers) 1.00 (95% CI
0.59–1.69; P = 0.997). There was similarly no association
after additional adjustment for SES and physical activity
1.00 (95% CI 0.59–1.69; P = 0.988) (Table 2). No sig-
nificant associations were observed for diuretic use or b-
blocker use with the risk of fractures. The association
between ACEIs or ARBs use and composite fractures was
not significantly modified by several clinically relevant
characteristics (P for interaction C0.10 for each; Fig. 1).
The corresponding adjusted HRs for hip fractures com-
paring ACEIs or ARBs use versus no use were 0.66 (95%
CI 0.28–1.55; P = 0.338), 0.89 (95% CI 0.32–2.47;
P = 0.820), and 0.89 (95% CI 0.32–2.47; P = 0.819)
respectively. There was also no evidence of any associa-
tions with risk of wrist fractures (Table 2).
Meta-analysis of published cohort studies
Ten articles based on 10 unique cohorts were identified to
have reported on the associations of ACEIs and/or ARBs
and risk of fractures (Appendix 6 of Electronic Supple-
mentary Material and Table 3) [22, 28, 29, 44–50].
Including the current study, there were 11 studies involving
3526,319 participants and [323,355 fractures. Quality
scores of included studies ranged from 5 to 8. In pooled
analyses of five studies each, the RRs for composite frac-
tures comparing ACEI users with non-users and ARB users
with non-users were 1.09 (95% CI 0.89–1.33) and 0.87
(95% CI 0.76–1.01) respectively. Comparing ACEI or
ARB users with non-users, the RR for composite fractures
in pooled analysis of three studies was 0.95 (95% CI
0.61–1.48) (Fig. 2). There was evidence of substantial
Table 2 Associations of use of ACEI or ARB and other antihypertensives with risk of fractures
Events/total Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Total fractures
No use 121/1093 ref ref ref
Diuretic use 3/50 0.36 (0.11–1.14) 0.083 0.34 (0.10–1.10) 0.072 0.35 (0.11–1.13) 0.080
b-blocker use 52/351 1.11 (0.79–1.54) 0.547 1.06 (0.71–1.59) 0.771 1.07 (0.72–1.61) 0.729
ACEI or ARB use 27/249 1.00 (0.66–1.52) 0.992 1.00 (0.59–1.69) 0.997 1.00 (0.59–1.69) 0.988
Hip fractures
No use 39/1093 ref ref ref
Diuretic use 1/50 0.31 (0.04–2.28) 0.250 0.31 (0.04–2.36) 0.258 0.33 (0.04–2.50) 0.281
b-blockers use 24/351 1.39 (0.83–2.34) 0.209 1.76 (0.91–3.39) 0.093 1.81 (0.94–3.49) 0.078
ACEI or ARB use 6/249 0.66 (0.28–1.55) 0.338 0.89 (0.32–2.47) 0.820 0.89 (0.32–2.47) 0.819
Wrist fractures
No use 30/1093 ref ref ref
Diuretic use 1/50 0.51 (0.07–3.81) 0.513 0.72 (0.09–5.78) 0.755 0.73 (0.09–5.88) 0.769
b-blocker use 5/351 0.47 (0.18–1.22) 0.120 0.52 (0.18–1.54) 0.239 0.53 (0.18–1.57) 0.251
ACEI or ARB use 6/249 0.95 (0.39–2.28) 0.905 1.19 (0.39–3.64) 0.764 1.20 (0.39–3.68) 0.749
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CI confidence interval, HR hazard ratio, ref reference
Model 1: Adjusted for age and sex
Model 2: Model 1 plus body mass index, smoking, history of diabetes, systolic blood pressure, prevalent hypertension, prevalent coronary heart
disease, prevalent heart failure, alcohol consumption, statin use, and calcium channel blocker use
Model 3: Model 2 plus socioeconomic status and physical activity
Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and…
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heterogeneity ([75%) among the included studies in all
pooled analyses.
The RR for hip fractures was 0.91 (95% CI 0.86–0.95)
in pooled analysis of two studies (comprising 1,282,483
participants and 42,481 hip fractures) that compared ACEI
users with non-users. In pooled analysis of these two
studies, the corresponding risk was 0.80 (95% CI
0.75–0.85) when ARB use was compared with no use.
Comparing ACEI or ARB users with non-users, the RR for
hip fractures in pooled analysis of four studies was 0.95
(95% CI 0.72–1.26) (Fig. 3).
Comparing ACEI users with non-users, the RR for
vertebral fractures was 1.69 (95% CI 1.40–2.04) and 0.81
(95% CI 0.69–0.95) for wrist fractures (Appendix 7 of
Electronic Supplementary Material). The RR for wrist
fractures was 0.68 (95% CI 0.53–0.87) and 0.76 (95% CI
0.61–0.94) for pelvic fractures, when ARB use was com-
pared with non-use (Appendix 8 of Electronic Supple-
mentary Material).
Comment
Summary of findings
In this population-based prospective study of middle-aged
to elderly men and women, there was no evidence of an
association of ACEI or ARB use with the risk of fractures
and this was consistent across several clinically relevant
subgroups. No evidence of significant associations with
risk of fractures was also observed for diuretic use or b-
blocker use. In pooled analysis of relevant published cohort
studies, use of ACEI or ARB was not associated with the
risk of composite fractures. However, pooled analysis of
two large studies showed that ACEI use was associated
with reduced risk of hip fractures [44, 47]. These two
studies also showed that ARB use was associated with
reduced risk of hip fractures. In pooled analysis of studies
that specifically evaluated ACEI or ARB use, no evidence
of decreased fracture risk was observed. The findings were
Age at survey (years)
< 65.3
≥ 65.3
Sex
Females
Males
Body mass index (kg/m2)
< 27.35
≥ 27.35
Systolic blood pressure (mmHg)
< 134.3
≥ 134.3
Total cholesterol (mmol/l)
< 5.45
≥ 5.45
Physical activity (kj/day)
< 381
≥ 381
Smoking status
Non-smokers
Current smokers
History of hypertension
No
Yes
Prevalent CHD
No
Yes
Prevalent heart failure
No
Yes
Subgroup
872
871
913
830
872
971
886
857
871
870
872
871
1,515
228
1021
722
1,255
488
1614
129
No. of participants
72
131
136
67
97
106
92
111
99
104
112
91
178
25
118
85
133
70
182
21
No. of total fractures
1.25 (0.59, 2.64)
0.96 (0.52, 1.78)
0.85 (0.45, 1.61)
1.29 (0.62, 2.65)
1.12 (0.50, 2.48)
0.87 (0.48, 1.60)
1.39 (0.72, 2.71)
0.82 (0.41, 1.63)
0.98 (0.50, 1.89)
1.03 (0.52, 2.05)
1.20 (0.65, 2.23)
0.72 (0.33, 1.56)
1.11 (0.65, 1.88)
0.32 (0.04, 2.49)
0.66 (0.09, 4.95)
0.98 (0.55, 1.76)
1.08 (0.59, 1.98)
0.87 (0.40, 1.91)
1.30 (0.75, 2.24)
0.29 (0.07, 1.20)
HR (95% CI)
.798
.453
.114
.462
.834
.577
.219
.525
.791
.084
P-value*
1.025 .05 .15 .25 .5 2.5 5 10
HR (95% CI) ACEI/ARB use versus no use
Fig. 1 Hazard ratios for composite fractures risk comparing ACEIs
or ARBs use with no use, by several participant level characteristics.
Hazard ratios were adjusted for age, sex, BMI, smoking, history of
diabetes, systolic blood pressure, prevalent hypertension, prevalent
CHD, prevalent heart failure, alcohol consumption, and use of statins,
or calcium channel blockers; ACEI angiotensin-converting enzyme
inhibitor, ARB angiotensin II receptor blocker, CHD coronary heart
disease, CI confidence interval, HR hazard ratio, *, P value for
interaction; cut-offs used for age, body mass index, systolic blood
pressure, total cholesterol, and physical activity are median values
S. K. Kunutsor et al.
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inconsistent for other site-specific fractures; findings from
some individual studies showed increased risk of vertebral
fractures and decreased risk of wrist fractures with ACEI
use [29, 44], whilst ARB use was associated with decreased
risk of wrist and pelvic fractures [44].
Comparison with previous work
Findings of our primary cohort analysis are consistent with
a number of cohort studies [28, 44, 48] that have been
published on the topic. There is however a possibility that
our null findings for ACEI or ARB use as well as diuretic
and b-blocker use could be due to the small sample that
used these medications and the low event rates in these
samples; therefore, the likelihood of insufficient power to
demonstrate any potential associations. We are however
unable to directly compare findings of our pooled analysis
in the context of previous studies, as the current study is the
first pooled analysis of published observational cohort
studies evaluating the use of RAS inhibitors and the risk of
fractures. In a recent pooled analysis of six case–control
studies, Cheng and colleagues showed an increased risk of
fractures with ACEI use and the association was stronger in
older users ([65 years) [27]. However, given the case–
control nature of the study designs, the temporal nature of
the relationship is difficult to ascertain. The authors also
called for cautious interpretation of the findings because of
the substantial heterogeneity between the studies. Though
our pooled analysis showed no evidence of an association
of any of the RAS inhibitors with risk of total fractures; use
of any of the RAS inhibitors was associated with reduced
risk of hip fractures, but this was based on a limited
ACEI
Chen, 2016
Kwok, 2016
Solomon, 2011
Choi, 2015
Torstensson, 2015
Subtotal
ARB
Chen, 2016
Kwok, 2016
Solomon, 2011
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Torstensson, 2015
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Current study
Yamamoto, 2015
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Subtotal
Author, year of publication
1,144
2,573
376,061
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1,586,554
1,144
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376,061
528,522
1,586,554
1,743
3,276
501,924
No. of participants
1.64 (1.01, 2.64)
0.69 (0.52, 0.91)
0.96 (0.90, 1.04)
1.68 (1.49, 1.91)
0.96 (0.95, 0.98)
1.09 (0.89, 1.33)
1.64 (1.01, 2.64)
0.28 (0.14, 0.58)
0.76 (0.68, 0.86)
1.00 (0.95, 1.05)
0.85 (0.83, 0.87)
0.87 (0.76, 1.01)
1.00 (0.59, 1.69)
0.65 (0.45, 0.92)
1.24 (1.17, 1.31)
0.95 (0.61, 1.48)
RR (95% CI)
1.05 .15 .25 .5 .75 1.5 2.5 5
RR (95% CI) comparing users with non-users
Fig. 2 Prospective studies of RAS inhibitors and risk of composite
fractures. The summary estimates presented were calculated using
random effects models; size of data markers are proportional to the
inverse of the variance of the relative ratio; ACEI angiotensin-
converting enzyme inhibitor, ARB angiotensin II receptor blocker, CI
confidence interval (bars), RR relative risk, RAS renin-angiotensin
system blockers
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number of studies. Therefore, further large-scale observa-
tional cohort studies are needed to confirm or refute the
current findings.
Possible explanations for findings
Given the close relationship between hypertension and its
detrimental effects on bone physiology [6–10], it has been
hypothesized that use of antihypertensive medications may
be useful in preventing these fractures. Indeed, use of
medications such as the thiazides and b-blockers have been
consistently demonstrated to be associated with reduced
risk of fractures [14–17]. However, findings from the pri-
mary cohort analysis showed no evidence of any associa-
tion of diuretics or b-blockers with the risk of fractures,
which could be attributed to the low event rates. Different
mechanisms have been postulated for the protective effects
of these medications on fracture risk. Thiazides modulate
calcium homeostasis and lower urinary calcium excretion
and therefore may reduce the risk of fractures via their
effects on bone mass [51]. Evidence also suggests that
thiazides have a direct effect on bone by promoting bone
formation [52], whereas b-blockers may exert their bene-
ficial effects on bone by blocking the adverse effects of the
sympathetic nervous system on bone tissue [53, 54].
Emerging evidence also suggests that RAS inhibitors may
reduce fracture risk, as the RAS has recently been shown to
play a role in bone tissue. Components of the RAS such as
angiotensin-converting enzyme (ACE) and angiotensin II
are found locally in several tissues [55–57] and have been
found to be expressed in osteoblasts and osteoclasts
[58, 59]. This suggests the existence of a local RAS in the
bone. Though angiotensin II has stimulatory effects on
osteoblasts [60, 61], it has been generally suggested to have
detrimental effects on bone structure by stimulating bone
resorption [59]. Angiotensin II also decreases the uptake of
calcium into bone [62], suppresses osteoblastic cell dif-
ferentiation and bone formation [63], and decreases
ACEI
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0.80 (0.75, 0.85)
0.89 (0.32, 2.47)
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RR (95% CI)
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RR (95% CI) comparing users versus non-users
Fig. 3 Prospective studies of RAS inhibitors and risk of hip fractures.
The summary estimates presented were calculated using random
effects models; size of data markers are proportional to the inverse of
the variance of the relative ratio; ACEI angiotensin-converting
enzyme inhibitor, ARB angiotensin II receptor blocker, CI confidence
interval (bars), RR relative risk, RAS renin-angiotensin system
blockers
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alkaline phosphatase activity [63]. Several studies in ani-
mal models have shown that inhibition of the angiotensin II
signalling pathway may prevent osteoporosis [64], increase
bone mass and strength [58, 65], and accelerate bone
healing and remodelling [66].
Taken together, the evidence suggests ACEIs and
ARBs, which inhibit the RAS, may help reduce fracture
risk by improving bone composition and structure. The
inconsistent associations between the use of RAS inhibitors
and risk of site-specific fractures as demonstrated in our
findings, may reflect the beneficial effects of angiotensin II
on bone and the differential effects of ACEIs and ARBs on
bone tissue. For example, Izu and colleagues showed in
mice that a type 2 ARB significantly enhanced bone mass,
whilst a type 1 ARB did not improve bone mass [58]. In the
experimental study by Bayar and colleagues, ACEI was
shown to have beneficial effects on fracture healing, whilst
losartan, an ARB, failed to demonstrate comparable ben-
eficial effects [67]. This differential effect may point to the
differences in the function of both RAS-acting drugs.
Further well-designed research is needed to delineate the
mechanistic pathways by which these RAS inhibitors act
on bone tissue.
Strengths and limitations
Our study had the advantage of utilizing a large-scale
population-based prospective cohort design with a pooled
analysis of all published observational cohort studies on the
topic in one comprehensive investigation. The primary
cohort study employed a sample of men and women who
were representative of the general middle-aged to elderly
population; there was complete follow-up for all partici-
pants; follow-up period was long with annually updated
incident outcomes; and the analysis was comprehensive
with adjustment for several confounders as well as
assessment for evidence of effect modification. Pooled
analysis of previous studies, including the current study,
enhanced power to assess the nature and magnitude of the
association. Limitations of the current study include lack of
separate data on ACEIs and ARBs and the duration of
blood pressure treatment in the primary cohort; absence of
data on relevant confounders such as markers of renal
function (e.g., creatinine, estimated glomerular filtration
rate), which influence bone health; the relatively young age
of study cohort at baseline precluded the ability to poten-
tially assess all fracture cases during the follow-up period
of the current study, as majority of fracture cases tend to
occur in the very elderly; the limited number of studies for
the pooled analysis; inconsistent definition of composite
fracture outcomes that did not enhance comparison across
studies; substantial heterogeneity across studies; and
inability to explore for publication bias because of the
small number of studies. In addition, due to the variable
adjustment by the eligible studies in the review, there was
the possibility of residual confounding. However, the
majority of studies reported estimates based on adjustment
for a comprehensive panel of confounders. Finally, a
number of these studies did not account for other antihy-
pertensive medication use such as thiazides and b-blockers
in their analysis.
Conclusion
In a middle-aged to elderly population of Caucasian men
and women, use of RAS inhibitors was not associated with
risk of composite fractures and this was confirmed by our
pooled analysis of previously published observational
cohort studies. A beneficial effect of use of RAS inhibitors
was observed for hip fractures, though the evidence was
limited; however, it was based on pooled analysis of two
large-scale cohort studies. Our study findings highlight the
fact there are still inconsistencies in the associations of use
of RAS inhibitors with risk of fractures. Further research is
needed to confirm or refute these findings and assess the
biological pathways underpinning any associations.
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